Nonalcoholic fatty liver disease, spleen and psoriasis: New aspects of low-grade chronic inflammation.

AIM To investigate spleen status in psoriasis and its relationship with hepatic steatosis, Psoriasis Area and Severity Index, and insulin resistance. METHODS Seventy-nine psoriatic patients who were not suffering from any chronic inflammatory disease were retrospectively selected for inclusion in this study, and their complete medical records were accessed. An age- and sex-matched group of 80 non-psoriatic, obese patients was included as a control. The following relevant data were collected: age, sex, weight, height, body mass index, waist circumference, blood pressure, insulin resistance status, age at psoriasis onset, and severity of psoriasis. Abdominal ultrasonography was performed to determine spleen longitudinal diameter (SLD), and hepatic steatosis grade. RESULTS The SLD of control obese patients was greater than that of psoriatic subjects (P = 0.013), but body mass index predicted the size of the spleen in psoriatic patients (P < 0.001). The SLD of psoriatic patients with normal weight was significantly reduced with respect to the overweight/obese psoriatic patients (P = 0.002). A multiple regression analysis revealed that body mass index was a unique predictor of the spleen size (P < 0.001). Finally, the disease duration predicted the spleen size in psoriatic subjects (P = 0.038). CONCLUSION This study shows a correlation between the SLD and the duration of psoriasis.

[1]  A. Hofman,et al.  Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. , 2014, Journal of the American Academy of Dermatology.

[2]  N. Balato,et al.  IL-33 is regulated by TNF-α in normal and psoriatic skin , 2014, Archives of Dermatological Research.

[3]  G. Jemec,et al.  Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. , 2013, Journal of the American Academy of Dermatology.

[4]  M. Keller,et al.  Psoriasis Vulgaris: An Evidence-Based Guide for Primary Care , 2013, The Journal of the American Board of Family Medicine.

[5]  L. Arends,et al.  Markers of systemic inflammation in psoriasis: a systematic review and meta‐analysis , 2013, The British journal of dermatology.

[6]  M. Napolitano,et al.  Psoriasis and osteoporosis: data from a Southern Italian population , 2012, Archives of Osteoporosis.

[7]  H. Yoshimatsu,et al.  A Novel Anti-inflammatory Role for Spleen-Derived Interleukin-10 in Obesity-Induced Inflammation in White Adipose Tissue and Liver , 2012, Diabetes.

[8]  M. Megna,et al.  Patient-physician relationship in patients with psoriasis. , 2012, Indian journal of dermatology, venereology and leprology.

[9]  N. Balato,et al.  Insulin-like Growth Factor-1, Psoriasis, and Inflammation: A Ménage à Trois? , 2011 .

[10]  A. Colao,et al.  Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. , 2010, World journal of gastroenterology.

[11]  M. Ghazizadeh,et al.  Pathogenic Mechanisms Shared between Psoriasis and Cardiovascular Disease , 2010, International journal of medical sciences.

[12]  Luis Puig,et al.  Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. , 2010, The Journal of investigative dermatology.

[13]  M. Schön,et al.  Managing comorbid disease in patients with psoriasis , 2010, BMJ : British Medical Journal.

[14]  G. Tarantino,et al.  Could inflammatory markers help diagnose nonalcoholic steatohepatitis? , 2009, European journal of gastroenterology & hepatology.

[15]  Zamir Halpern,et al.  Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. , 2009, AJR. American journal of roentgenology.

[16]  G. Tarantino,et al.  Young adult obese subjects with and without insulin resistance: what is the role of chronic inflammation and how to weigh it non-invasively? , 2009, Journal of Inflammation.

[17]  E. Christophers Comorbidities in psoriasis , 2006, Clinics in dermatology.

[18]  R. Torella,et al.  The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. , 2006, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[19]  C. Griffiths,et al.  Psoriasis: epidemiology, clinical features, and quality of life , 2005, Annals of the rheumatic diseases.

[20]  A. Martí,et al.  Decreased splenic mRNA expression levels of TNF-α and IL-6 in diet-induced obese animals , 2004, Journal of Physiology and Biochemistry.

[21]  C. D. Krause,et al.  Interleukin-10 and related cytokines and receptors. , 2004, Annual review of immunology.

[22]  W Sterry,et al.  IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. , 1998, The Journal of clinical investigation.

[23]  L. Witts,et al.  SALMONELLAE AND SHIGELLAE , 1954 .

[24]  5. CLASSICAL METHODS OF ANALYSIS OF MATCHED DATA , 2009 .

[25]  A. J. van der Lely,et al.  Chronic inflammation in psoriasis and obesity: implications for therapy. , 2006, Medical hypotheses.

[26]  Yoshito Tsushima,et al.  Spleen Enlargement in Patients with Nonalcoholic Fatty Liver , 2004, Digestive Diseases and Sciences.

[27]  A. Martí,et al.  Decreased splenic mRNA expression levels of TNF-alpha and IL-6 in diet-induced obese animals. , 2004, Journal of physiology and biochemistry.